Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

MARVEL: Evaluation of EMVI positive rectal cancer

Molecular pathologic and MRI investigation of the prognostic and redictive importance of extramural VEnous invasion in rectal cancer

The treatment for rectal cancer has improved significantly over the last 25 years, however, recent advances in radiology, surgery and cancer treatment mean that we are in an exciting position to improve results further. More accurate diagnostic techniques are allowing us to gain significant amounts of information on tumour characteristics at an early stage. Yet we do not fully understand what these tumour characteristics mean in the long term and how best to tailor patients’ treatments in order to mitigate these factors. One of these characteristics which we do know that leads to a worse prognosis is called extramural venous invasion (EMVI), whereby some of the cancer cells spread into the nearby blood vessels. Although we are now able to accurately identify this phenomenon using MRI scans, it is not clear as to what effect standard treatments have on this. We believe that the presence of this feature in rectal cancer leads to it having a distinct genetic make-up.

More recently, new analytic techniques are becoming available for gene and molecular analysis in cancers. Using these techniques, it is possible to identify differences in the genetic profiles between EMVI positive and EMVI negative adenocarcinoma in rectal cancer. A better understanding of the molecular differences between these two tumour subtypes may enable the subsequent integration of molecular information into prognostication, and development of objective molecular-pathologically based treatment algorithms. This information may also uncover novel therapeutic targets, and have wider biological utility.

Patients who decide to enrol in the study will not have to undertake any additional procedures or treatments outside their planned care. We will compare their MRI scan before and after chemoradiotherapy. We will use new analytical techniques to assess the underlying genetic and molecular profiles of the biopsies and surgery specimens to identify differences. We will continue to monitor the progress of the patients and disease progression through their visits to the outpatient department.

By identifying the differences in the make-up of those cancers that demonstrate EMVI and those that do not, we will be able to target treatments at these differences and thus reduce the effect it has on the long term prognosis. By using the longer term data on how patients’ progress compared to what is happening to the degree of EMVI, we will be able to identify those patients which may benefit from further treatment after their surgery and more frequent follow-up.

Link to UKCRN.

References

Dresen, R.C., et al., Local recurrence in rectal cancer can be predicted by histopathological factors. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009. 35(10): p. 1071-7.

Talbot, I.C., et al., The clinical significance of invasion of veins by rectal cancer. The British journal of surgery, 1980. 67(6): p. 439-42.

Smith, N.J., et al., MRI for detection of extramural vascular invasion in rectal cancer. AJR. American journal of roentgenology, 2008. 191(5): p. 1517-22.

Baumhoer, D., et al., Impact of using elastic stains for detection of venous invasion in the prognosis of patients with lymph node negative colorectal cancer. International journal of colorectal disease, 2010. 25(6): p. 741-6.

 

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy